Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: Results from a randomized controlled trial

Journal of Affective Disorders

Volumn 69, Issue 1-3, 2002, Pages 109-118

  Namjoshi, Madhav A ^a   Rajamannar, Gopalan ^a   Jacobs, Thomas ^a   Sanger, Todd M ^a   Risser, Richard ^a   Tohen, Mauricio F ^a,b   Breier, Alan ^a   Keck Jr , Paul E ^c  

^a ELI LILLY AND COMPANY   (United States)

^b MCLEAN HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Direct medical costs; Mania; Olanzapine; Quality of life

Indexed keywords

FLUOXETINE; LITHIUM; OLANZAPINE; PLACEBO; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIRENZEPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; BIPOLAR DISORDER; COST; COST BENEFIT ANALYSIS; ECONOMICS;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HUMAN; MALE; PIRENZEPINE; QUALITY OF LIFE; SUPPORT, NON-U.S. GOV'T; BENZODIAZEPINES; HUMANS;

EID: 0036018491     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(01)00310-X     Document Type: Article

References (20)

1. Antipsychotics in bipolar disorder
2. A pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar 1 disorder
3. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder: Psychometric performance of four self-report measures
4. The economics of lithium therapy
5. The MOS 36-Item Short-Form Health Survey (SF-36). II: Psychometric and clinical tests of validity in measuring physical and mental health constructs
6. A mental health capitation program: II. Cost-benefit analysis
7. Lithium: A brake on the rising cost of mental illness
8. Telephone versus in-person clinical and health status assessment interviews in patients with bipolar disorder
9. The economic burden of affective disorders
10. Statistical analysis of cost outcomes in a randomized controlled clinical trial
11. Long-term olanzapine therapy in the stabilization and maintenance treatment of bipolar I disorder
12. Beyond the Hamilton depression scores in long-term treatment of manic-melancholic patients: Prediction of recurrence of depression by quality of life measurements
13. Olanzapine versus placebo in the treatment of acute mania
14. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
15. An economic evaluation of manic-depressive illness - 1991
16. A rating scale for mania: Reliability, validity, and sensitivity